A Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Inhaled CHF6001 DPI in Asthmatics
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The study is designed to look at the safety, tolerability and efficacy of 2 different doses
of the study drug (CHF6001, a PDE4 inhibitor) in asthmatics, when given by inhalation, once a
day for 9 days. The efficacy will be evaluated by measuring the protective effect of CHF 6001
after an allergen challenge.